2-(4-chlorophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine | 1043506-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(4-chlorophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine
• CAS: 1043506-54-2
• 化学式: C₂₄H₂₃ClN₄
• 分子量: 402.926
• InChiKey: SVBTVDBPLSHECO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  异烟酸 、 2-(4-chlorophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以18%的产率得到(4-((2-(4-chlorophenyl)-6-phenylimidazo[1,2-a]pyridin-3-yl)methyl)piperazin-1-yl)(pyridin-4-yl)methanone
  参考文献：
  名称：

  [EN] SLC2A TRANSPORTER INHIBITORS
  [FR] INHIBITEURS DU TRANSPORTEUR SLC2A

  摘要：

  提供了一种用于药物的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式（I）：其中A和Z可以相同也可以不同，分别独立地选自C、N、O和S；每个X可以相同也可以不同，独立地选自C、N、O和S；R1和R5可以存在也可以不存在，可以相同也可以不同，分别选自H和一个取代或未取代的有机基团；Z与每个X形成一个环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代为H或一个取代或未取代的有机基团；所有环中的原子之间的键包括X、A和Z可能独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。

  公开号：

  WO2014187922A1
• 作为产物：
  描述：

  2-氨基-5-苯基吡啶 在 三乙酰氧基硼氢化钠 、 三氟乙酸 、 三氯氧磷 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 65.0h， 生成 2-(4-chlorophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  [EN] SLC2A TRANSPORTER INHIBITORS
  [FR] INHIBITEURS DU TRANSPORTEUR SLC2A

  摘要：

  提供了一种用于药物的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式（I）：其中A和Z可以相同也可以不同，分别独立地选自C、N、O和S；每个X可以相同也可以不同，独立地选自C、N、O和S；R1和R5可以存在也可以不存在，可以相同也可以不同，分别选自H和一个取代或未取代的有机基团；Z与每个X形成一个环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代为H或一个取代或未取代的有机基团；所有环中的原子之间的键包括X、A和Z可能独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。

  公开号：

  WO2014187922A1

文献信息

• IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
  申请人：Mulbaier Marcel

  公开号：US20140221354A1

  公开（公告）日：2014-08-07

  The present invention provides novel imidazo[1,2-a]pyridine compounds that are useful in therapy of diseases and disorders. The novel compounds inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders, wherein X is CH 2 , CH 2 CH 2 or C═O; R 1 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R 1a which are identical or different; R 2 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R 2a which are identical or different; R 3 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, fluorinated C 1 -C 2 -alkyl C(O)R 4 ; where R 1a , R 2a and R 4 are as defined in the claims and the specification.

  本发明提供了新型咪唑[1,2-a]吡啶化合物，用于治疗疾病和疾病障碍。这些新型化合物抑制缺氧条件下缺氧诱导因子（HIF）介导的转录和信号的激活。在一个方面，本发明的化合物可用于制备治疗或预防炎症性疾病、高增殖性疾病或疾病障碍、缺氧相关病理和过度血管化疾病的药物。还提供了一种药物组合物，包括本发明的化合物和第二种治疗剂或辐射，用于治疗或预防上述疾病或疾病障碍，其中X为CH2、CH2CH2或C═O；R1为苯基或C-结合的单环5-或6-成员杂环，其中苯基和单环5-或6-成员杂环未被取代或携带1、2、3、4或5个相同或不同的R1a基团；R2为苯基或C-结合的单环5-或6-成员杂环，其中苯基和单环5-或6-成员杂环未被取代或携带1、2、3、4或5个相同或不同的R2a基团；R3为氢、C1-C6-烷基、C1-C4-烷氧基-C1-C4-烷基、氟化C1-C2-烷基C(O)R4；其中R1a、R2a和R4如权利要求和说明书中所定义。
• SLC2A TRANSPORTER INHIBITORS
  申请人：IOMET PHARMA LTD.

  公开号：US20160120863A1

  公开（公告）日：2016-05-05

  Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula: wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R 1 and R 5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

  提供了一种用于医药的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式：其中A和Z可以相同或不同，且分别独立地选自C、N、O和S；每个X可以相同或不同，且独立地选自C、N、O和S；R1和R5可以存在或不存在，可以相同或不同，且分别选自H和取代或未取代的有机基团；Z与每个X形成环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代H或取代或未取代的有机基团；其中，包括X、A和Z在内的所有环中的原子之间的键可以独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。
• IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY
  申请人：EMBLEM Technology Transfer GmbH

  公开号：EP2691392A1

  公开（公告）日：2014-02-05
• [EN] IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY<br/>[FR] COMPOSÉS D'IMIDAZO[1,2-A]PYRIDINE POUR L'UTILISATION EN THÉRAPIE
  申请人：ELARA PHARMACEUTICALS GMBH

  公开号：WO2012130322A1

  公开（公告）日：2012-10-04

  The present invention provides novel imidazo[1,2-a]pyridine compounds that are useful in therapy of diseases and disorders. The novel compounds inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders. wherein X is CH2, CH2CH2 or C=O; R1 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R1a which are identical or different; R2 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R2a which are identical or different; R3 is hydrogen, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkyl C(O)R4; where R1a, R2a and R4 are as defined in the claims and the specification.
• [EN] SLC2A TRANSPORTER INHIBITORS<br/>[FR] INHIBITEURS DU TRANSPORTEUR SLC2A
  申请人：IOMET PHARMA LTD

  公开号：WO2014187922A1

  公开（公告）日：2014-11-27

  Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R1 and R5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

  提供了一种用于药物的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式（I）：其中A和Z可以相同也可以不同，分别独立地选自C、N、O和S；每个X可以相同也可以不同，独立地选自C、N、O和S；R1和R5可以存在也可以不存在，可以相同也可以不同，分别选自H和一个取代或未取代的有机基团；Z与每个X形成一个环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代为H或一个取代或未取代的有机基团；所有环中的原子之间的键包括X、A和Z可能独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。